Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc.
| AMARIN PHARMA, INC., AMARIN PHARMACEUTICALS IRELAND LIMITED and MOCHIDA PHARMACEUTICAL CO., LTD. |
| HIKMA PHARMACEUTICALS USA INC., HIKMA PHARMACEUTICALS PLC and HEALTH NET LLC |
| 23-1169 |
| November 21, 2022 |
| U.S. Court of Appeals, Federal Circuit |
| Patent Infringement (Fed. Qst.) |
Opinions
We have the following opinions for this case:
| Description |
|---|
 AMARIN PHARMA, INC. v. HIKMA PHARMACEUTICALS USA INC.
|
| AMARIN PHARMA, INC. v. HIKMA PHARMACEUTICALS USA INC. |
Docket Report
RSS Track this Docket
This docket was last retrieved on December 20, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 11 Official caption revised to reflect non-participation of Appellee Health Net LLC. (see attached). Service as of this date by the Clerk of Court. [891779] [KMH] [Entered: 12/20/2022 11:24 AM] |
| Filing 10 **TEXT ONLY** ORDER granting motion to extend time to file brief [ # 9 ] filed by Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Mochida Pharmaceutical Co., Ltd. The opening brief is due 03/21/2023. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [891778] [KMH] [Entered: 12/20/2022 11:23 AM] |
| Filing 9 MOTION of Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Mochida Pharmaceutical Co., Ltd. to extend the time to 03/21/2023 to file brief. Service: 12/14/2022 by email. [890734] [23-1169] [Nathan Kelley] [Entered: 12/14/2022 05:40 PM] |
| Filing 8 Notice to Appellee Health Net LLC: The record of this case indicates that no Entry of Appearance under FCR 47.3(b), Certificate of Interest under FCR 47.4, and/or Docketing Statement under FCR 33.1(a) has been filed. Failure to file required documents may result in dismissal or other action as deemed appropriate by the court. See FCR 25(h). Service as of this date by the Clerk of Court. [889743] [KMH] [Entered: 12/09/2022 04:10 PM] |
| Filing 7 Certificate of Interest for Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Mochida Pharmaceutical Co., Ltd.. Service: 12/05/2022 by email. [888372] [23-1169] [Nathan Kelley] [Entered: 12/05/2022 04:05 PM] |
| Filing 6 Docketing Statement for the Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Mochida Pharmaceutical Co., Ltd.. Service: 12/05/2022 by email. [888368] [23-1169] [Nathan Kelley] [Entered: 12/05/2022 04:03 PM] |
| Filing 5 Entry of appearance for Nathan K. Kelley; Mark T. Smith as counsel for Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Mochida Pharmaceutical Co., Ltd.. Service: 12/05/2022 by email. [888366] [23-1169] [Nathan Kelley] [Entered: 12/05/2022 04:02 PM] |
| Filing 4 Docketing Statement for the Appellees Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals PLC. Service: 12/05/2022 by email. [888335] [23-1169] [Charles Klein] [Entered: 12/05/2022 03:13 PM] |
| Filing 3 Certificate of Interest for Appellees Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals PLC. Service: 12/05/2022 by email. [888332] [23-1169] [Charles Klein] [Entered: 12/05/2022 03:10 PM] |
| Filing 2 Entry of appearance for Charles B. Klein; Eimeric Reig-Plessis; Claire A. Fundakowski; Alison M. King as counsel for Appellees Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals PLC. Service: 12/05/2022 by email. [888316] [23-1169] [Charles Klein] [Entered: 12/05/2022 02:56 PM] |
| Filing 1 Appeal docketed. Received: 11/14/2022. [885281] Entry of Appearance due 12/05/2022. Certificate of Interest is due on 12/05/2022. Docketing Statement due 12/05/2022. Appellant/Petitioner's brief is due 01/20/2023. [KMH] [Entered: 11/21/2022 10:22 AM] |
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the U.S. Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
